TheralinkTheralink

  • Theralink
    • The Theralink platform
    • The Theralink Assay
    • Request RPPA Analyte List
    • RPPA Clinical Publications
    • RPPA Research Publications
    • RPPA Technical Publications
  • About
    • Overview
    • Oncologists
    • Mission Statement
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
  • News & Media
    • Press Releases
    • Media & Articles
    • Theralink Blog
  • Biopharmas
    • Overview
    • Explore Technology
    • Explore Targets
    • Explore Pathways
    • Request Pathway Quote
    • Conference Abstracts
    • FAQ
  • Investor Relations
    • Market Opportunity
    • Investor Relations Email Alerts
    • Company Information
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
    • Contact
    • Investors Relations FAQ
  • Contacts

Press releases

Theralink   →  Media Room   →  Press releases
Posted on November 24, 2020November 24, 2020

Theralink® Technologies Announces Partnership with Perthera to Facilitate and Accelerate Access to its Unique Phosphoprotein and Drug Target Activation Testing in the U.S.

DENVER, Colorado — November 16, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a precision o...
Read More
Posted on September 30, 2020December 10, 2020

Theralink® Technologies Appoints Thomas Chilcott as Chief Financial Officer

DENVER, Colorado — September 29, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a molecular...
Read More
Posted on September 24, 2020December 10, 2020

Theralink® Technologies Announces Corporate Name Change

  DENVER, Colorado — September 24, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), fo...
Read More
Posted on September 15, 2020October 21, 2020

OncBioMune d/b/a Theralink® Technologies Announces Strategic Translational Research Collaboration with BioMed Valley Discoveries

Golden, Colorado – September 15th, 2020 – Theralink Technologies, Inc., a molecular profiling company (OTC: OBMP), today annou...
Read More
Posted on September 10, 2020September 18, 2020

Theralink® Technologies to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16th

DENVER, Colorado — September 9, 2020 — OncBioMune d/b/a Theralink Technologies (OTC: OBMP) (“Theralink” or the “Compan...
Read More
Posted on September 9, 2020

Theralink® Technologies Achieves Milestone, CLIA Certification for its Golden, CO Laboratory

Expects to Begin Receiving, Testing and Billing for Patient’s Breast Cancer Tumor Specimens in Q4 2020 -- DENVER, Colorado...
Read More
Posted on August 25, 2020

Theralink® Technologies to Present at the LD 500 Virtual Conference on September 1st

DENVER, Colorado — August 25, 2020 — OncBioMune d/b/a Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company...
Read More
Posted on July 22, 2020December 10, 2020

Theralink® Technologies Appoints Michael Fanelli Senior Director, Biopharma Commercial Operations

  Mr. Fanelli joins the Theralink® team having previously held positions at Metabolon Inc., Core Diagnostics, Nanostring...
Read More
Posted on July 8, 2020March 28, 2022

Theralink® Technologies Announces Strategic Agreement with VieCure to Improve Outcomes for Breast Cancer Patients Being Treated in Community Oncology Settings

  Theralink® Technologies Announces Strategic Agreement with VieCure to Improve Outcomes for Breast Cancer Patients Being...
Read More
Posted on June 17, 2020June 17, 2020

OncBioMune d/b/a Theralink® Technologies Launches New Corporate Website

  Golden, Colorado – June 17, 2020 – OncBioMune (OTC: OBMP) d/b/a Theralink Technologies, a molecular profiling compan...
Read More
Previous page 1 2 3 Next page

Recent Posts

  • Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry
  • Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
  • Theralink® Technologies Announces New PLA Code and Information Submittal to Medicare Contractors for the Theralink Assay for Advanced Breast Cancer Patients
  • Early Results Show >90% Actionability and >75% Clinical Utility for Theralink® Technologies’ Lab Developed Test for Advanced Breast Cancer Patients
  • Theralink® Technologies Announces Change of Ticker Symbol and CUSIP
Theralink Technologies intends to be a market leader in precision medicine for more effective cancer treatments

Menu

  • About
  • Investors
  • Contact
  • Privacy Policy

OUR SERVICES

  • Biopharmas
  • Oncologists
  • Media Room

Press Releases

  • Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry
  • Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
  • Theralink® Technologies Announces New PLA Code and Information Submittal to Medicare Contractors for the Theralink Assay for Advanced Breast Cancer Patients
Copyright © 2022 Theralink. All rights reserved.